Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

World Journal of Surgical Oncology

Research

Hiroshi Nanjyo¹  Norihiko Tsuchiya²  Kazuyuki Numakura²  Tomonori Habuchi²  Takashi Obara²  Yohei Horikawa²  Mitsuru Saito²  Shinya Maita²  Shigeru Satoh²  Takamitsu Inoue²  Hiroshi Tsuruta²  Shintaro Narita²  Teruaki Kumazawa³ 

[1] Department of Pathology, Akita University School of Medicine, Akita, Japan;Department of Urology, Akita University School of Medicine, Akita, Japan;Department of Urology, Senboku General Hospital, Daisen, Japan;

关键词: chemohormonal therapy;    prostate cancer;    docetaxel;    estramustine phosphate;    complete androgen blockade;    androgen deprivation;   

DOI  :  10.1186/1477-7819-10-1

 received in 2011-09-07, accepted in 2012-01-04,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundTo assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).MethodsComplete androgen blockade followed by 6 cycles of docetaxel (30 mg/m2) with estramustine phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed.ResultsNo patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease.ConclusionWe found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.

【 授权许可】

Unknown   
© Narita et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.